SEARCH

SEARCH BY CITATION

References

  • 1
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May; 344(19):143441.
  • 2
    Prevrhal S, Krege JH, Chen P, Genant H, Black DM. Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin. 2009 Apr; 25(4):9218.
  • 3
    Krege JH, Wan X. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone. 2012 Jan; 50(1):1614.
  • 4
    McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005 Aug; 165(15):17628.
  • 5
    Jakob F, Oertel H, Langdahl B, Barrett A, Karras K, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Barker C, Lems WF, Marin F. Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol. 2012 Jan; 166(1):8797.
  • 6
    Hadji P, Zanchetta JR, Russo L, Recknow CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2011 Aug; 23(8):214150.
  • 7
    Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008 Oct; 23(10):1591600.
  • 8
    Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004 May; 19(5):74551.
  • 9
    Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008 Oct; 93(10):378593.
  • 10
    Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008 Mar; 93(3):85260.
  • 11
    Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005 Aug; 353(6):56675.
  • 12
    Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R. Effect of prior and ongoing raloxifene therapy on response to PTH therapy. Osteoporos Int. 2008 Apr; 19(4):52935.
  • 13
    Wermers RA, Recknor CP, Cosman F, Xie L, Glass EV, Krege JH. Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporos Int. 2008 Jul; 19(7):105565.
  • 14
    Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab. 2009 Oct; 94(10):377280.
  • 15
    Keaveny TM, Hoffmann PF, Singh M, Palermo LK, Bilezikian JP, Greenspan SL, Black DM. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. 2008 Dec; 23(12):197482.
  • 16
    Keaveny TM, McClung WR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K. Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone. 2012 Jan; 50(1):16570.
  • 17
    Keaveny TM. Biomechanical computed tomography—non-invasive bone strength analysis using clinical CT scans. Ann NY Acad Sci. 2010 Mar; 1192:5765.
  • 18
    Keaveny TM, Donley DW, Hoffman PF, Mitlak BH, Glass EV, San Martin JA. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res. 2007 Jan; 22(1):14957.
  • 19
    Lewiecki M, Keaveny TM, Kopperdahl D, Genant HK, Engelke K, Fuerst T, Kivitz A, Davies RY, Fitzpatrick LA. Once-monthly oral ibandraonate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2009 Jan; 94(1):17180.
  • 20
    Wang X, Sanyal A, Cawthon PM, Palermo L, Jekir M, Christensen J, Ensrud KE, Cummings SR, Orwoll E, Black DM. Osteoporotic Fractions in Men (MrOS) Research Group, Keaveny TM. Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans. J Bone Miner Res. 2012 Apr; 27(4):80816.
  • 21
    Orwoll ES, Marshall LM, Nielson CM, Cummings SR, Lapidus J, Cauley JA, Ensrud K, Lane N, Hoffmann PR, Kopperdahl DL, Keaveny TM. Finite element analysis of the proximal femur and hip fracture risk in older men. J Bone Miner Res. 2009 Mar; 24(3):47583.
  • 22
    Kopperdahl DL, Hoffmann P, Sigurdsson S, Aspelund T, Siggeirsdottir K, Eiriksdottir G, Harris T, Gudnason VG, Keaveny TM. Enhancement of hip fracture prediction using finite element analysis of CT scans. J Bone Miner Res. 2010; 25(Suppl S1):S114. Abstract.
  • 23
    Melton LJ 3rd, Riggs BL, Keaveny TM, Achenbach SJ, Hoffman PF, Camp JJ, Rouleau PA, Bouxsein ML, Amin S, Atkinson EJ, Robb RA, Khosla S. Structural determinants of vertebral fracture risk. J Bone Miner Res. 2007 Dec; 22(12):188592.
  • 24
    Melton LJ 3rd, Riggs BL, Keaveny TM, Achenbach SJ, Kopperdahl D, Camp JJ, Rouleau PA, Amin S, Atkinson EJ, Robb RA, Therneau TM, Khosla S. Relation of vertebral deformities to bone density, structure, and strength. J Bone Miner Res. 2010 Sep; 25(9):192230.
  • 25
    Amin S, Kopperdahl DL, Melton LJ 3rd, Achenback SJ, Therneau TM, Riggs BL, Keaveny TM, Khosla S. Association of hip strength estimates by finite element analysis with fractures in women and men. J Bone Miner Res. 2011 Jul; 26(7):1593600.
  • 26
    Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, Vahle J, Brommage R, Jerome CP, Turner CH. Teriparatide [PTH(1–34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res. 2004 Apr; 19(4):6239.
  • 27
    Chen P, Glass EV, Krege JH. Early changes in bone turnover markers (BTMs) predict vertebral strength changes in teriparatide- or alendronate-treated postmenopausal women with osteoporosis [abstract]. In: ENDO 2007 Program & Abstracts. Toronto: Endocrine Society; June 2007.
  • 28
    Borggrefe J, Graeff C, Nickelsen TN, Marin F, Gluer CC. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS Study. J Bone Miner Res. 2010 Mar; 25(3):47281.